Yumanity Therapeutics : Regulation FD Presentation - Form 8-K

Kineta Unveils New VISTA Biomarker Data and KVA12123 Phase 1/2 Clinical Trial Update at AACR Annual Meeting 2023


SEATTLE, April 17, 2023 - Kineta, Inc. , a clinical-stage... | April 17, 2023

Related Keywords

United States ,American ,Jacques Bouchy ,Thierry Guillaudeux ,John Mullaly ,Kineta Inc ,Exchange Commission ,Facebook ,American Association For Cancer Research ,Linkedin ,Nasdaq ,Lifesci Advisors ,Investor Relations Business Development ,Kineta Unveils New ,Trial Update ,American Association ,Cancer Research ,Annual Meeting ,Chief Scientific Officer ,Therapeutic Benefit ,Private Securities Litigation Reform Act ,Annual Report ,Business Development ,Sci Advisors ,Yumanity Therapeutics Stock Exchange ,News ,Information ,Press Release ,Vineta ,Nveils ,Few ,Rista ,Biomarker ,Data ,End ,Va12123 ,Hase ,Linical ,Trial ,Update ,It ,Racr ,Nnual ,Meeting ,Pril ,023 Ymtx Us98872l1026 ,